1. Home
  2. Directory
  3. New York
  4. Nyack
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1821521220

DANIEL COLE M.D.
Prescription History 1821521220
Internal Medicine - Hematology & Oncology in Nyack, NY

NPI Status: Active since April 04, 2017

Contact Information

160 N MIDLAND AVE
NYACK, NY
ZIP 10960
Phone: (845) 480-7440
Fax: (845) 480-7448

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DANIEL COLE M.D., an active Hematology & Oncology specialist practicing in Nyack, NY. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 101 documented patient claims. Among these therapy options, the most frequently utilized medication is Valacyclovir, which accounts for 52 claims alone.

Medication Index

A
O
S
V
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 22
30-Day Fills 34.0
Days Supply 1,020
NY State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills142.7
Peer Average Days Supply4,244
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.6% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $569.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.89

State Avg Cost Per Claim

$28.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 244
NY State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.2
Peer Average Days Supply290
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $137.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.57

State Avg Cost Per Claim

$9.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Single Use Swab

Generic Formulation: Alcohol Antiseptic PadsSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 14
30-Day Fills 16.0
Days Supply 480
NY State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills51.6
Peer Average Days Supply1,531
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.3% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $38.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.76

State Avg Cost Per Claim

$2.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Valacyclovir

Generic Formulation: Valacyclovir HclSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 52
30-Day Fills 58.0
Days Supply 1,740
NY State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills32.9
Peer Average Days Supply768
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 126.1% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,185.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.03

State Avg Cost Per Claim

$46.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.

Therapeutic Applications

Valacyclovir is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster). In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. Valacyclovir is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, this medication is used to reduce the number of future episodes. Valacyclovir is an antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Valacyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DANIEL COLE M.D. provides transparency into local medical care patterns within Nyack, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.